High-dose chemotherapy with autologous stem cell transplantation for multiple myeloma: What predicts the outcome? Experience from a developing country

Bone Marrow Transplantation

Volumn 43, Issue 6, 2009, Pages 481-489

  Kumar, L ^a   Ghosh, J ^a   Ganessan, P ^a   Gupta, A ^a   Hariprasad, R ^a   Kochupillai, V ^a  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMIFOSTINE; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; ITRACONAZOLE; MELPHALAN; PHENIRAMINE MALEATE; PREDNISOLONE; THALIDOMIDE; VINCRISTINE; ZOLEDRONIC ACID;

ADULT; AGED; ALOPECIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER DIAGNOSIS; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DEVELOPING COUNTRY; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPNEA; ENGRAFTMENT SYNDROME; FEMALE; FEVER; HEMATOPOIETIC STEM CELL; HUMAN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; NAUSEA; PERIPHERAL BLOOD STEM CELL; PLEURA EFFUSION; PRIORITY JOURNAL; RASH; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; WEIGHT GAIN;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DEVELOPING COUNTRIES; DISEASE PROGRESSION; FEMALE; HUMANS; INDIA; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 63949087366     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.343     Document Type: Article

References (39)

1. Kyle R, Rajkumar SV. Multiple myeloma. Blood 2008; 111: 2962-2972.
2. Kumar L, Vikram P, Kochupillai V. Multiple myeloma: Recent advances in management. Nat Med J India 2006; 19: 80-89.
3. Selby PJ, Mac Elwain TJ, Nandi AC, Ferren TJ, Powles RL, Tillyer CR et al. Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol 1987; 66: 55-62.
4. Powles R, Raje N, Milan S, Millar B, Shepherd V, Mehta J et al. Outcome assessment of a population based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment. Bone Marrow Transplant 1997; 20: 435-443.
5. Blade J, Esteve J, Rives S, Martínez C, Rovira M, Urbano-Ispizua A et al. High-dose therapy autotransplantation intensification vs continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution. Bone Marrow Transplant 2000; 26: 845-849.
6. Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A et al Results of high-dose therapy for 1000 patients with multiple myeloma: Durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95: 4008-4010.
7. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective randomized trial of autologous bone marrow and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-97.
8. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. Medical Research Council Adult Leukaemia Working Party high-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. New Engl J Med 2003; 348: 1875-1883.
9. Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M et al High-dose therapy and autologous stem cell compared with conventional treatment in myeloma patients aged 55 to 65 years: Long term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005; 23: 9227-9233.
10. Lenhoff S, Hjorth M, Holmberg I, Turesson I, Westin J, Nielssen JL et al. Impact on survival of high dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: A population based study. Blood 2000; 95: 7-11.
11. Koreth J, Cutler CS, Djulbegovic B, Behl R, Schlossman RL, Munshi NC et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 2007; 13: 183-196.
12. Levy V, Katsahian S, Fermand JP, Mary JY, Chevret S. A meta-analysis on data from 575 patients with multiple myeloma randomly assigned to either high dose therapy or conventional therapy. Medicine 2005; 84 250-260.
13. Kumar L, Raju GMK, Ganessan K, Shawgi S, Menon H, Wadhwa J et al. High dose chemotherapy followed by autologous stem cell transplantation in multiple myeloma. Nat Med J India 2003; 16: 16-20.
14. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36 842-854.
15. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
16. Raju GMK, Kochupillai V, Kumar L. Storage of haematopoietic stem cells for autologous bone marrow transplantation. Nat Med J India 1995; 8: 216-221.
17. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA et al. Regimen related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
18. Blade J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998; 102 1115-1123.
19. Ozer H, George SL, Schiffer CA, Rao K, Rao PN, Wurster-Hill DH et al Prolonged subcutaneous administration of recombinant alpha interferon in patients with previously untreated Philadelphia chromosome positive chronic phase chronic myelogenous leukemia: Effect on remission duration and survival Cancer and Leukemia Group B study 8583. Blood 1993; 82: 2975-2984.
20. Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D et al Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106: 35-39.
21. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021-1030.
22. Breitkreutz I, Lokhorst HM, Raab MS, Holt B, Cremer FW, Herrmann D et al. Thalidomide in newly diagnosed multiple myeloma: Influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia 2007; 21: 1294-1299.
23. Blijlevens N, Schwenkglenks M, Bacon P, D'Addio A, Einsele H, Maertens J et al. European Blood and Marrow Transplantation Mucositis Advisory Group. Prospective oral mucositis audit: Oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy - European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol 2008; 26: 1519-1525.
24. Spencer A, Horvath N, Gibson J, Prince HM, Herrmann R, Bashford J et al. Australasian Leukemia and Lymphoma Group. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplant 2005; 35: 971-977.
25. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al. Palifermin for oral mucositis after intensive therapy for hematological cancers. New Engl J Med 2004; 351: 2590-2598.
26. Cahill RA, Spitzer TR, Mazumder A. Marrow engraftment and clinical manifestations of capillary leak syndrome. Bone Marrow Transplant 1996; 18: 177-184.
27. Mossad S, Kalaycio M, Sobecks R, Pohlman B, Andresen S, Avery R et al Steroids prevent engraftment syndrome after autologous hematopoietic stem cell transplantation without increasing the risk of infection. Bone Marrow Transplant 2005; 35: 375-381.
28. Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 14: 822-829.
29. van de Velde HJ, Liu X, Chen G, Cakana A, Deraedt W, Bayssas M. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 2007; 92: 1399-1406.
30. Pineda-Roman M, Bolejack V, Arzoumanian V, Anaissie E, van Rhee F, Zangari M et al. Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. Br J Haematol 2007; 136: 393-399.
31. O'Shea D, Giles C, Terpos E, Perz J, Politou M, Sana V et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: A single centre experience in 211 patients. Bone Marrow Transplant 2006; 37: 731-737.
32. Krejci M, Buchler T, Hajeck R, Svobodnik A, Krivanova A, Pour L et al Prognostic factors for survival after autologous transplantation: A single centre experience in 133 multiple myeloma patients. Bone Marrow Transplant 2005; 35: 159-164.
33. Nadal E, Gine E, Blade J, Esteve J, Rosifiol L, Fernandez Aviles F et al. High dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: Predictors of complete remission. Bone Marrow Transplant 2004; 33: 61-64.
34. Alexanian R, Weber D, Giralt S, Dimoopoules M, Delasalle K, Smith T et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001; 27: 1037-1043.
35. International Bone Marrow Transplant Registry/Autologous Blood & Marrow Transplant Registry (IBMTR/ABMTR). News Letter 2000; 7: 3-10.
36. Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C et al. High dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma. Upfront or rescue treatment? Results of a multicenter sequential randomized trial. Blood 1998; 92: 3131-3136.
37. Sengar M, Kumar L, Ganessan K, Mohanty S, Wadhwa J, Kochupillai V. Role of post transplant maintenance therapy in multiple myeloma: Results from a developing country. Proc Am Soc Clin Oncol 2005; 24: 6731 (abstract).
38. Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L et al. Inter-Groupe Francophone du Myélome (IFM). Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006; 108: 3289-3294.
39. Haessler J, Shaughnessy Jr JD, Zhan F, Crowley J, van Rhee F, Epstein J et al. Benefit of complete response in multiple myeloma limited to high risk subgroup identified by gene expression profiling. Clin Cancer Res 2007; 13: 7073-7079.